Spectrum: Local Antimicrobial Stewardship, for Billings Clinic

Clindamycin

C. diff Risk

High

Oral Bioavailability

Excellent

Approximate Cost

PO ~$1/day
IV ~ $14-17/day

Spectrum Of Activity

General Spectrum of Activity

Spectrum Of Activity

General Spectrum of Activity

Antibiogram Data

Dosing

Pediatric

IV40 mg/kg/day divided q6-8h

PO30-40 mg/kg/day divided q6-8h

Adult

Usual indications
600 mg IV q8h

Necrotizing SSTI or toxic shock syndrome
900mg IV q8h

Oral Dosing
300 mg PO q6h

General Information

Acceptable Uses

Acceptable Uses

In addition to other agents for necrotizing fascitis or toxic shock syndrome.

Common Usage

Common Usage

  • Susceptible infections and surgical prophylaxis in setting of IgE mediated beta-lactam allergy.

  • For decreasing toxin production in toxic shock syndrome.

  • Anaerobic infections above the diaphragm, especially dental infection.

  • Gram positive skin and soft tissue infections including necrotizing fasciitis as an adjunctive agent to a beta-lactam for reducing toxin production.

  • Skin & soft tissue infections involving susceptible MRSA.

Drug Monitoring

Drug Monitoring

Monitor for diarrhea.

Major Interactions

Major Interactions

  • Muscle relaxants, e.g., Atracurium, Baclofen, Diazepam.

  • St. Johns Wort

Additional Information

Additional Information

Not a great empiric drug for coverage of MRSA based on local susceptibility profiles.

High risk for C. difficile infection.

Pharmacology

Pharmacology

Antimicrobial class: Lincosamide

Pregnancy category: B

Average serum half life: 2.4 hours

Biliary penetration: Therapeutic

CSF penetration: Poor

Lung penetration: Therapeutic

Urine penetration: Poor

No renal adjustment required